245 related articles for article (PubMed ID: 17041286)
61. A comparative study of antipsychotic medication taking in people with schizophrenia.
McCann TV; Deans C; Clark E; Lu S
Int J Ment Health Nurs; 2008 Dec; 17(6):428-38. PubMed ID: 19128290
[TBL] [Abstract][Full Text] [Related]
62. [Schizophrenic patients' quality of life--association with coping, locus of control, subjective well-being, satisfaction and patient-judged caregiver burden].
Schmid R; Neuner T; Cording C; Spiessl H
Psychiatr Prax; 2006 Oct; 33(7):337-43. PubMed ID: 17024583
[TBL] [Abstract][Full Text] [Related]
63. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia.
Savilla K; Kettler L; Galletly C
Aust N Z J Psychiatry; 2008 Jun; 42(6):496-504. PubMed ID: 18465376
[TBL] [Abstract][Full Text] [Related]
64. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
65. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study.
Adrianzén C; Arango-Dávila C; Araujo DM; Ruíz I; Walton RJ; Dossenbach M; Karagianis J
Hum Psychopharmacol; 2010 Aug; 25(6):439-47. PubMed ID: 20737517
[TBL] [Abstract][Full Text] [Related]
66. Insight into severe mental illness, hope, and quality of life of persons with schizophrenia and schizoaffective disorders.
Hasson-Ohayon I; Kravetz S; Meir T; Rozencwaig S
Psychiatry Res; 2009 May; 167(3):231-8. PubMed ID: 19394091
[TBL] [Abstract][Full Text] [Related]
67. A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication.
Gray R; Rofail D; Allen J; Newey T
J Adv Nurs; 2005 Oct; 52(1):31-7. PubMed ID: 16149978
[TBL] [Abstract][Full Text] [Related]
68. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
69. The long term--maximising potential for rehabilitation in patients with schizophrenia.
Fagiolini A; Goracci A
Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S123-9. PubMed ID: 17336767
[TBL] [Abstract][Full Text] [Related]
70. Results of a thematic analysis to explore the experiences of patients with schizophrenia taking antipsychotic medication.
Rofail D; Heelis R; Gournay K
Clin Ther; 2009 Jun; 31 Pt 1():1488-96. PubMed ID: 19698906
[TBL] [Abstract][Full Text] [Related]
71. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Nasrallah H; Morosini P; Gagnon DD
Psychiatry Res; 2008 Nov; 161(2):213-24. PubMed ID: 18848731
[TBL] [Abstract][Full Text] [Related]
72. Critical evaluation of the use of research tools in evaluating quality of life for people with schizophrenia.
Hewitt J
Int J Ment Health Nurs; 2007 Feb; 16(1):2-14. PubMed ID: 17229269
[TBL] [Abstract][Full Text] [Related]
73. Heterogeneity of treatment effects in schizophrenia.
Stroup TS
Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
[TBL] [Abstract][Full Text] [Related]
74. The burden of depressive symptoms in people with schizophrenia.
Conley RR
Psychiatr Clin North Am; 2009 Dec; 32(4):853-61. PubMed ID: 19944888
[TBL] [Abstract][Full Text] [Related]
75. [Adherence to neuroleptic treatment of schizophrenic patients].
Blondiaux I; Alagille M; Ginestet D
Encephale; 1988; 14(6):431-8. PubMed ID: 2906607
[TBL] [Abstract][Full Text] [Related]
76. Novelty seeking and medication adherence in patients with schizophrenia.
Aukst Margetić B; Jakovljević M; Ivanec D; Tošić G; Margetić B
Psychiatry Res; 2011 Mar; 186(1):141-3. PubMed ID: 20630601
[TBL] [Abstract][Full Text] [Related]
77. Partial agonists and schizophrenia: theoretical developments for the development of mental health nursing.
Jones M; White J; Gray R
J Psychiatr Ment Health Nurs; 2009 Jun; 16(5):409-15. PubMed ID: 19538596
[TBL] [Abstract][Full Text] [Related]
78. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
[TBL] [Abstract][Full Text] [Related]
79. The influence of adherence to antipsychotics medication on the quality of life among patients with schizophrenia in Indonesia.
Endriyani L; Chien CH; Huang XY; Chieh-Yu L
Perspect Psychiatr Care; 2019 Apr; 55(2):147-152. PubMed ID: 29578605
[TBL] [Abstract][Full Text] [Related]
80. Quality of life measurement during antipsychotic drug therapy of schizophrenia.
Voruganti LN; Heslegrave RJ; Awad AG
J Psychiatry Neurosci; 1997 Jul; 22(4):267-74. PubMed ID: 9262049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
